Effects of Dexmedetomidine on Delirium After Living Donor Renal Transplantation in Adult Patients

Tao Zhang

Status and phase

Unknown

Phase 4

Conditions

Postoperative Delirium After Living Donor Renal Transplantation

Treatments

Drug: Dexmedetomidine

Drug: Saline

Study type

Interventional

Funder types

Other

Identifiers

NCT02509949

DDRT

Details and patient eligibility

About

Delirium, an acute change in mental status, is a serious medical complication among hospitalized patients. Syndrome of delirium involves agitation, sleep disturbance, affective disorders and cognitive disruptions.

One vulnerable period for developing delirium is in the postoperative days. Postoperative delirium often initiates a cascade of adverse consequences including an increase in length of stay and hospital costs, and greater mortality. The investigators have observed that the incidence of postoperative delirium in patients after renal transplantation is about 20-30% in our hospital.

Several studies have revealed that dexmedetomidine, as a widely used sedative during anesthesia, can decrease the incidence of postoperative delirium after cardiac surgery. The investigators aim to examine whether administration of dexmedetomidine can reduce postoperative delirium after living donor renal transplantation in adult patients.

Enrollment

100 estimated patients

Sex

All

Ages

18 to 59 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

age > 17 and < 60 years;
American Society of Anesthesiology (ASA) I-III;
admitted for living donor renal transplantation.

Exclusion criteria

Patients with a history of drug abuse;
preoperative history of schizophrenia, epilepsy, parkinsonism, use of cholinesterase inhibitor, inability to communicate in the preoperative period (coma, profound dementia, or language barrier).